<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065362</url>
  </required_header>
  <id_info>
    <org_study_id>33954: RESIST-NPC</org_study_id>
    <secondary_id>P01CA094237</secondary_id>
    <nct_id>NCT02065362</nct_id>
  </id_info>
  <brief_title>TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC</brief_title>
  <official_title>Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have nasopharyngeal carcinoma (NPC). This study is a gene transfer research study
      using special immune cells.

      Most patients with NPC show evidence of infection with the virus that causes infectious
      mononucleosis Epstein Barr virus (EBV) before or at the time of their diagnosis. EBV is found
      in the cancer cells of almost all patients with advanced stage NPC, suggesting that it may
      play a role in causing the disease. The cancer cells infected by EBV are able to hide from
      the body's immune system and escape destruction. We want to see if special white blood cells,
      called T cells, that have been trained to recognize and kill special parts of EBV infected
      cells can survive in patient's blood and affect the tumor.

      We already have given EBV-specific cytotoxic T cells to 30 patients with active NPC and have
      seen anti-tumor activity in 14 of 30 patients. We are now trying to find out if we can
      improve this treatment.

      First, we want to give T cells where more of the cells recognize at least two of the four EBV
      proteins expressed on NPC cells. We call these cells NPC-specific cytotoxic T cells.

      Second, we found that T cells work better if we add a receptor to the T cells called DNR
      (Dominant Negative Receptor). DNR makes T cells resistant to TGFbeta, a factor secreted by
      cancer cells that helps them escape being killed by the immune system. In this study we will
      therefore place the DNR gene into NPC-specific T cells (DNR.NPC-specific T cells).

      In other clinical studies using T cells, some investigators found that giving chemotherapy
      before the T cell infusion can improve the amount of time the T cells stay in the body and
      therefore the effect the T cells can have. Giving chemotherapy before a T cell infusion is
      called lymphodepletion since the chemotherapy is specifically chosen to decrease the number
      of lymphocytes in the body. Decreasing the number of patient's lymphocytes first should allow
      the T cells we infuse to expand and stay longer in their body, and potentially kill cancer
      cells more effectively.

      The chemotherapy we will use for lymphodepletion is a combination of cyclophosphamide and
      fludarabine. Cyclophosphamide and fludarabine are the chemotherapy agents most commonly used
      for lymphodepletion in immunotherapy clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood will be collected from the patient to make LMP/BARF1/EBNA1 (NPC)-specific T cells. To
      grow NPC-specific T cells we have to use special cells called antigen-presenting cells, which
      train the patient's T cells to be NPC specific. Antigen presenting cells, so called monocytes
      or dendritic cells, will be grown/isolated from the patient's blood. In addition, we use a
      cell line called K562 as antigen-presenting cells that has had genes put inside it, which
      encourage the patient's T cells to grow. K562 cells are cancer cells. As such, if injected
      they could cause cancer. The cells have been treated with radiation so they cannot grow.

      These antigen-presenting cells are coated with a specially produced mixture of LMP, EBNA1 and
      BARF protein fragments called peptides. These coated antigen-presenting cells are then used
      to generate the patient's NPC-specific T cells in the presence of growth factors. To get the
      DNR to attach to the surface of these NPC-specific T Cells, we also inserted the DNR gene
      into the NPC-specific T cells (DNR.NPC-specific T cells). This is done with a virus called a
      retrovirus that has been made for this study. This virus will carry the DNR gene into the
      cells.

      Once we have made sufficient numbers of DNR.NPC-specific T cells we will freeze the cells and
      test them to make sure they recognize EBV proteins present in NPC.

      Patients will get treated with 1) either two doses of DNR.NPC-specific T cells (the second
      dose will be given 2 weeks after the first dose) or 2)cyclophosphamide and fludarabine for 3
      days before receiving the DNR.NPC-specific T cells.

      The cyclophosphamide and fludarabine will be given through a needle inserted into a vein or
      patient's port-a-cath).

      The T cells will be thawed and infused through a central line, or through a vein in the
      patient's arm over 1 to 10 minutes. Patients will be followed in the clinic after the
      infusion for 1 to 4 hours.

      All of the treatments will be given by the Center for Cell and Gene Therapy at Texas
      Children's Hospital or Houston Methodist Hospital.

      Medical tests before treatment:

      Before being treated, the patient will receive a series of standard medical tests:

      Physical exam Imaging Study Blood tests to measure blood cells, kidney and liver function
      Measurements of the tumor by routine imaging studies. We will use the imaging study that was
      used before to follow the patient's tumor: Computer Tomogram (CT), Magnetic Resonance Imaging
      (MRI), or Positron Emission Tomography (PET/CT)

      Medical tests during and after treatment:

      The patient will receive standard medical tests when they are getting the infusions and
      after:

      Physical exams Blood tests to measure blood cells, kidney and liver function Imaging study 8
      weeks after the 1st T-cell infusion(for patients receiving only DNR.NPC-specific T cells ) or
      Imaging study 6 weeks after the T-cell infusion (for patients receiving fludarabine and
      cyclophosphamide before DNR.NPC-specific T-cell infusion).

      To learn more about the way the DNR.NPC-specific T cells are working and how long they last
      in the body, an extra 60ml or 3ml/kg of body weight of blood (whichever is less) will be
      taken pre-chemotherapy (for the patients receiving chemotherapy), on the day of the T-cell
      infusion (before and at the end of the T-cell infusion), 1, 2, 3, 4. 6, and 8 weeks( the last
      time point only for patients receiving DNR.NPC-specific T-cells only) after the T-cell
      infusion and every 3 months for 1 year, every 6 months for 4 years, then yearly for a total
      of 15 years. One additional blood sample might be drawn 3 to 4 days post the 1st T-cell
      infusion; this is optional. This volume is considered safe, but may be decreased if the
      patient is anemic. In addition to the blood tests, the patient will receive 2 imaging studies
      as stated above.

      During the time points listed above, if the DNR.NPC-specific T cells are found in patient's
      blood at a certain amount an extra 5ml of blood may need to be collected for additional
      testing.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2033</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a dose limiting toxicity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determine the safety of escalating doses of intravenous infusions of autologous TGFbeta-resistant NPC-specific cytotoxic T-lymphocytes with lymphodepleting chemotherapy for dose levels 2 and 3 in patients with EBV-positive nasopharyngeal carcinoma (NPC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of T cells in the blood after the infusions</measure>
    <time_frame>15 years</time_frame>
    <description>Determine the survival and the immune function of TGFbeta-resistant NPC specific T cells.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with a response to the T cells</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assess the anti-viral and anti-tumor effects of TGFbeta-resistant NPC specific T cells.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>EBV-positive Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNR.NPC-specific T cells</intervention_name>
    <description>Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:
Dose Level 1:
Day 0: 2 x 10^7 cells/m^2
Day 14: 2 x 10^7 cells/m^2
The doses are calculated according to the total T cell number.</description>
    <arm_group_label>DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNR.NPC-specific T cells + cyclophosphamide + fludarabine</intervention_name>
    <description>Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.
Each patient will receive infusions according to the following dosing schedule:
Dose Level 2:
Cy/Flu on Days -4 to -2 and then 4 x 10^7 cells/m^2 on Day 0, Day 1 or Day 2
Dose Level 3:
Cy/Flu on Days -4 to -2 and then 1 x 10^8 cells/m^2 on Day 0, Day 1, or Day 2</description>
    <arm_group_label>DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patient must meet the following eligibility inclusion criteria at the time of
        PROCUREMENT:

          -  Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory
             disease

          -  EBV positive tumor

          -  Informed consent explained to, understood by and signed by patient/guardian.
             Patient/guardian given copy of informed consent

        The patient must meet the following eligibility criteria to be included for TREATMENT:

          -  Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory
             disease

          -  EBV positive tumor

          -  Patients with life expectancy greater than or equal to 6 weeks

          -  Bilirubin less than or equal to 3x upper limit of normal

          -  AST less than or equal to 5x upper limit of normal

          -  ANC&gt;750/microliter

          -  Platelets &gt; 50,000/microliter

          -  Hgb &gt; 8.0g/dl (can be transfused)

          -  Creatinine less than or equal to 2x upper limit of normal for age, Creatinine
             clearance (as estimated by Cockcroft Gault or Schwartz) greater than or equal to 60
             ml/min

          -  Pulse oximetry of &gt; 90% on room air

          -  Off investigational therapy for 4 weeks prior to study entry

          -  Karnofsky or Lansky score of greater than or equal to 50%

          -  Sexually active patients must be willing to utilize one of the more effective birth
             control methods during the study and for 6 months after the study is concluded. The
             male partner should use a condom.

          -  Informed consent explained to, understood by and signed by patient/guardian.
             Patient/guardian given copy of informed consent.

        Exclusion Criteria:

        At time of Procurement:

        â€¢Known HIV positivity

        At time of Treatment:

          -  Pregnant or lactating

          -  Severe intercurrent infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher DeRenzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine/Texas Children's Hospital /Houston Methodist Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Helen Heslop</investigator_full_name>
    <investigator_title>Director CAGT</investigator_title>
  </responsible_party>
  <keyword>EBV positive</keyword>
  <keyword>TGFbeta</keyword>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>cytotoxic T lymphocytes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

